Zymeworks Announces Participation in Upcoming Investor Conferences

Rhea-AI Summary

Zymeworks Inc. (NASDAQ: ZYME), a clinical-stage biotechnology firm, will participate in two upcoming investor conferences. Management will hold one-on-one meetings and present at the 2023 Bloom Burton & Co. Healthcare Investor Conference on April 25 in Toronto. Additionally, they will participate in the Stifel 2023 Targeted Oncology Days virtually on April 26. Presentations and webcasts will be available on their website. Zymeworks is focused on developing innovative biotherapeutics, including the HER2-targeted bispecific antibody, zanidatamab, currently in various clinical trial phases.

VANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences:

• 2023 Bloom Burton & Co. Healthcare Investor Conference. Zymeworks’ management will participate in one-on-one meetings and present on April 25^th in Toronto, CA.
• Stifel 2023 Targeted Oncology Days. Zymeworks’ management will participate virtually in one-on-one meetings and present on April 26^th.

All presentations and webcasts will be available on Zymeworks’ website at http://ir.zymeworks.com/events-and-presentations.

About Zymeworks Inc.

Zymeworks Inc. (Nasdaq: ZYME) is a global biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks' mission is to make a meaningful difference for people impacted by difficult-to-treat cancers and other serious diseases. Zymeworks' complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using Zymeworks' proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz), granting each of BeiGene and Jazz with exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab is currently being evaluated in global Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials as a treatment for patients with HER2-expressing cancers. Zymeworks' next clinical candidate, zanidatamab zovodotin (ZW49), is a HER2-targeted bispecific antibody-drug conjugate (ADC) developed using Zymeworks' proprietary Azymetric™ and ZymeLink™ Auristatin technologies. Zanidatamab zovodotin is currently being evaluated in a Phase 1 clinical trial for patients with a variety of HER2-expressing, HER2-amplified or HER2-mutant cancers. Zymeworks is also advancing a deep pipeline of product candidates based on its experience and capabilities in both ADC and multispecific antibodies (MSAT). In addition to Zymeworks' wholly owned pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230403005172/en/

Investor Inquiries:

Jack Spinks

Director, Investor Relations

(604) 678-1388

ir@zymeworks.com

Media Inquiries:

Diana Papove

Director, Corporate Communications

(604) 678-1388

media@zymeworks.com

Source: Zymeworks Inc.

FAQ

When will Zymeworks present at the Bloom Burton & Co. Healthcare Investor Conference?

Zymeworks will present at the Bloom Burton & Co. Healthcare Investor Conference on April 25, 2023.

What is Zymeworks' stock symbol?

Zymeworks' stock symbol is ZYME.

When is Zymeworks participating in the Stifel 2023 Targeted Oncology Days?

Zymeworks will participate virtually in the Stifel 2023 Targeted Oncology Days on April 26, 2023.

Where can I find Zymeworks' conference presentations?

Zymeworks' conference presentations and webcasts will be available on their website.

What is the focus of Zymeworks' biotherapeutics development?

Zymeworks develops novel, multifunctional biotherapeutics targeting difficult-to-treat cancers and serious diseases.